What Changed in 2026: The New HRT Guidelines Every Woman Should Know
Day 20 of the 30-day Perimenopause Series.
The Warning Your Mother Was Given
If you are in your forties or fifties, there is a good chance you absorbed a rule about hormones long before you ever needed one. Hormone therapy causes breast cancer. Hormone therapy causes heart attacks. Hormone therapy is a risk you take for vanity.
You may have watched your mother stop hers abruptly in 2002 or 2003, on the advice of a doctor who had just read the same headline she had. She may have been fine. She may have spent the next three years not sleeping and never once connected the two.
That rule was built on one study, read badly, and it held for more than twenty years.
In February 2026 the FDA removed the boxed warnings on HRT. What your mother was told is not what we know now. Ask again. With better data.
What Actually Changed
On November 10, 2025, the FDA and the Department of Health and Human Services announced they would begin stripping the boxed warnings from menopausal hormone therapy products, specifically the language on cardiovascular disease, breast cancer, and probable dementia.
In February 2026 the first revised labels were actually approved - six products in the first batch, with that language removed. The revisions reach across all four categories: systemic combination therapy, systemic estrogen-alone therapy, systemic progestogen-alone therapy, and low-dose vaginal estrogen.
The decision followed a review of the scientific literature, an expert panel convened in July 2025, and a public comment period. It was not an overnight reversal, even though it landed like one.
One boxed warning stays. Systemic estrogen-alone therapy still carries the endometrial cancer warning for women who have a uterus - and it should. That warning is the entire reason progesterone is prescribed alongside estrogen in the first place.
The FDA also moved timing to the front of the conversation: therapy started within ten years of the onset of menopause, generally before age 60.
Why the Old Warning Was Wrong, and What It Cost
The Women's Health Initiative was not fraudulent and it was not junk science. It was a large, serious trial that answered a different question than the one most women were asking.
The average participant was 63 years old and more than a decade past her final period. Many already carried cardiovascular risk. The regimen studied was conjugated equine estrogen with medroxyprogesterone acetate - not the transdermal estradiol and micronized progesterone most commonly used today. And the 2002 announcement led with relative risk, which sounded enormous and translated into a small absolute difference.
Then that finding was applied wholesale to a 46-year-old with hot flashes who had not slept through the night in a year.
Prescriptions collapsed. A generation of clinicians trained afterward learned to say no reflexively, and a generation of women learned not to ask. FDA Commissioner Makary said in the November announcement that tens of millions of women had been denied benefit "because of a medical dogma." I do not usually find myself nodding at a press release. I nodded at that one.
The Timing Window
This is the single most useful idea to take away, and it is the one the old warning flattened completely.
Hormone therapy started close to the menopausal transition and hormone therapy started fifteen years afterward are not the same intervention, and they do not carry the same risk profile. Started within roughly ten years of the final period, or before 60, the balance generally favors treatment for women with bothersome symptoms - and the FDA's own summary points to better outcomes in that window, including on fracture risk. Started at 68, in a woman with two decades of accumulated vascular change, the calculation is genuinely different and deserves to be treated that way.
Perimenopause sits squarely inside that window. If you are 44 and being told to wait until your periods stop entirely before anyone will discuss this with you, that advice is not built on the current evidence.
What Removing a Warning Does Not Mean
I want to be as careful on this side as on the other, because the pendulum is already swinging and the marketing has gotten loud.
Removing a boxed warning is not the same as adding an indication. Hormone therapy is approved to treat symptoms and to prevent bone loss. It is not approved as a general anti-aging or longevity drug, and anyone selling it that way is ahead of the evidence.
It does not mean risk is zero. It means the risks were overstated, misapplied to the wrong ages, and presented without the corresponding benefits. Those risks still belong in a real conversation with someone who knows your history.
It does not mean every woman needs it. Plenty of women move through this transition without treatment and do beautifully. The point is that the choice was taken away from an entire generation, and it is being handed back.
And it does not license the compounded, unregulated, pellet-based market to claim vindication. That is a different product category with different oversight, and it is tomorrow's post.
Vaginal Estrogen - The Quietest and Most Important Change
If you read one section twice, make it this one.
Low-dose vaginal estrogen was carrying the same frightening boxed warning as systemic therapy despite being a fundamentally different exposure - it acts locally, with minimal systemic absorption. The Menopause Society, in responding to the FDA announcement, singled this out as the change it most welcomed, noting the warning may have deterred women from a therapy it describes as safe and effective for genitourinary symptoms.
I have watched women read that label at the pharmacy counter and quietly decide to live with pain during sex, recurrent urinary tract infections, and burning instead. That warning cost real comfort for no good reason. We will spend a whole day on this later in the series, because it deserves one.
Who Still Needs a Careful Conversation
A label change does not erase individual history. These are the situations where hormone therapy needs a genuine, unhurried discussion - sometimes a different route, sometimes a different dose, sometimes a different answer altogether. None of them is automatically a no, and none of them is something to decide from a blog post.
A personal history of breast cancer or another estrogen-sensitive cancer.
A history of blood clots, stroke, or heart attack. Route matters here: transdermal delivery bypasses first-pass liver metabolism and carries a different clotting profile than oral.
Unexplained vaginal bleeding. This gets worked up before anything is prescribed, not after.
Active liver disease.
Migraine with aura, where the route and dose discussion genuinely matters.
Being well past 60, or more than ten years out from your final period, when starting fresh.
And if you have a uterus, you need a progestogen alongside systemic estrogen. That is not optional and it is not negotiable.
The Menopause Society's position after the FDA announcement is the right one: comorbidities, personal and family history, symptoms, and preferences all get reviewed together. Individualized, not algorithmic.
The Mental Health Piece
This is my lane, so I will be precise about it.
Hormone therapy is not an antidepressant, and I would never present it as one. But there is a real research literature on estradiol and mood during the perimenopausal transition specifically, and the fear generated by that boxed warning kept the option off the table for a lot of women whose depression started when their cycles did.
What I see clinically is women who have cycled through three or four antidepressants with partial response, whose sleep is fragmented, whose symptoms track visibly with the calendar, and whose hormonal picture has never once been part of the conversation. Sometimes the answer is still an antidepressant. Sometimes it is therapy, or sleep, or grief work, or an SSRI plus everything else. But it should be on the table, and for twenty years it was not.
How to Have the Conversation
Lead with symptoms and their impact, not with a lab result. Perimenopause is diagnosed clinically, and a single hormone level on a random day tells you very little.
Ask directly: given my age, my history, and how close I am to menopause, what is my actual risk-benefit picture? A good clinician will not find that question annoying.
Ask about route - patch, gel, spray, or pill - and why they are recommending the one they chose.
Ask about vaginal estrogen as a separate question. It often gets lost inside the bigger systemic discussion, and the answer may be different.
Ask what would make them stop or change course, and when you will be reassessed. A plan with no checkpoints is not a plan.
If you are told flatly that hormone therapy causes breast cancer and the conversation ends there, you have been handed a 2002 answer. Get a second opinion. The Menopause Society maintains a directory of certified practitioners, and it is worth using.
A Note to Your People
If a woman you love says she is thinking about hormone therapy, resist the urge to tell her what happened to your aunt in 2004. She has heard that story her whole life. What she has not had is anyone helping her get an appointment with someone current. Do that instead.
Whole-Person Steps
If you were turned down for hormone therapy before November 2025, ask again. The guidance you were refused under has changed.
Write down your symptoms, how long you have had them, and what they are costing you at work and at home. Bring that page to the appointment.
Write down your history too: clots, strokes, heart disease, liver disease, migraines with aura, and any personal or family history of breast or gynecologic cancer. This is the information that shapes the answer.
Ask about vaginal estrogen separately, especially if you have painful sex, urinary urgency, or recurrent urinary tract infections.
Get your mammogram and your blood pressure current before the conversation. Both belong in the decision anyway.
Keep doing the unglamorous work regardless of what you decide. Strength training, protein, sleep, and alcohol all move the same outcomes hormone therapy is being asked to fix.
If You Are in Utah
At Integrative Mind Body Psychiatry, I treat the whole person - which means asking about your cycle, your sleep, and your hormonal history in a psychiatric visit, and coordinating with the clinician who manages your hormone therapy rather than pretending the two are unrelated. Telehealth for adults, adolescents, and women in hormonal transitions across Utah. Insurance accepted through Headway. Learn more at integrativemindbodypsychiatry.com.
This post is general education, not medical advice. It does not create a provider-patient relationship and it is not a substitute for evaluation by a clinician who examines you.
Tomorrow: Day 21 - Bioidentical vs Synthetic: Cutting Through the Confusion.
Respectfully, and with real care,
Beth Makar, RN, Dual-MSN, PMHNP-BC
Comments